LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round.
The financing was led by China Biopharmaceuticals, with participation from Pudong Venture Capital, Zhangjiang Haoheng, and returning investors Qiming Venture Partners and Shanghai Biomedical Fund.
The company plans to use the funds to advance its clinical pipeline, particularly its lead assets LM-302 and LM-108, and to expand its innovative discovery platforms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze